In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

The global leukemia therapeutics treatment market is expected to grow at a CAGR of 6.6% during the forecast period (2025–2035). Factors such as the rising prevalence of leukemia, increasing adoption ...

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec. 5, 2024 — The first comprehensive map of the dramatic changes that take place in the blood system over the ...

in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and idiopathic cytopenia of unknown significance (ICUS). 1 “Neutrophils can promote or suppress tumor growth.

Faiz Anwer, MD, reported receiving personal fees from Celgene, BMS, and Carobou outside the submitted work.

Leukemia can refer to all cancers affecting the white blood cells. How the cancer spreads can depend on the type of leukemia and how aggressive it is. Leukemia is a cancer of the blood cells ...

In the U.S., BREYANZI is approved for treating relapsed or refractory large B-cell lymphoma (LBCL) after at least one prior therapy, as well as relapsed or refractory chronic lymphocytic leukemia or ...